Brief: FDA Grants Lantern Pharma Orphan Drug Designation For LP-284
05/01/2023 14:32
Jan 5 (Reuters) - Lantern Pharma Inc. LTRN.O :
* FDA GRANTS LANTERN PHARMA ORPHAN DRUG DESIGNATION FOR DRUG
CANDIDATE LP-284 IN MANTLE CELL LYMPHOMA
* LANTERN PHARMA - ANTICIPATING FILING IND WITH FDA,
INITIATING
FIRST-IN-HUMAN PHASE 1 TRIAL FOR LP-284 IN B-CELL NON-HODGKIN'S
LYMPHOMAS BY MID 2023
Source text for Eikon: ID:nBwbZryJda
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments